Cyprotex Launches its New Catalogue for Experimental and Predictive ADME and PK Services.
Cyprotex today (23rd April 2008) announces the launch of its new catalogue for experimental and predictive ADME (absorption, distribution, metabolism and excretion) and PK (pharmacokinetic) services. The catalogue covers the three main product lines, Cloe® Screen, Cloe® Select and Cloe® Predict, which provide a fully integrated solution in the area of ADME and PK throughout the drug discovery and development process.
Commenting on the launch, Mr. Robert Atwater, Cyprotex's Chief Executive Officer, said: "We are delighted to introduce our exciting new catalogue which covers our up-to-date broad range of products and services. The catalogue includes many of the recent introductions to our portfolio such as Cloe® Select and the Cyprotex Discovery Bus. Expanding on this platform is a key focus for 2008."
The Cloe® technology encompasses both experimental and predictive services. Our unique Cloe® Screen service couples robust protocols with state-of-the-art automation enabling Cyprotex to offer an unrivalled combination of high quality, cost effective data with rapid turnaround. Cloe® Select, which was launched earlier this month, provides a more bespoke and flexible service for later stage, in-depth studies. Cyprotex has a wealth of experience in predictive modelling including expertise in PB-PK (physiologically based-pharmacokinetic) and QSAR (quantitative structure activity relationship) techniques. Cloe® Predict can be coupled with Cloe® Screen or Cloe® Select to provide an integrated experimental and predictive approach.
For further information:
Helen Gill PhD, Product Development Manager
Tel: +44 (0)1625 505 100